Clinical trials
Transplantation Infection clinical trials
Below are recruiting transplantation infection clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06050148RecruitingPhase 2/Phase 3
Fecal Transplant to Prevent Repeat Urinary Tract Infections
This trial tests whether a fecal microbiota transplant (a procedure that transfers healthy bacteria from a donor's stool into your gut) can help prevent repeat urinary tract infections in women who have frequent infections.
HelsinkiAges 18–90 - NCT04832607RecruitingPhase 3
Donor T-cell treatment for stubborn CMV, EBV, or Adenovirus after transplant
This Phase 3 trial tests giving special immune cells from your stem-cell donor to treat difficult-to-control viral infections after a stem cell transplant. It may help your body fight the virus when standard antiviral medicines haven’t worked well enough.
BrusselsAges 2 months+ - NCT05708508RecruitingPhase 3
Immune-guided vs universal medicine to prevent CMV after kidney transplant
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
RouenAges 18–75 - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for resistant gut bacteria before stem cell transplant
This study tests an experimental oral medicine called SNIPR001. It is designed to reduce resistant E. coli bacteria in the gut before your stem cell transplant, possibly lowering the risk of infection.
Duarte, CaliforniaAges 18 years+ - NCT06066957RecruitingPhase 2
Oral letermovir to prevent CMV after heart or lung transplant
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT06829719Recruiting
Using TTV virus to manage immune drugs in kidney transplant
This trial uses a virus called TTV to see if it can help doctors safely adjust immunosuppression drugs in kidney transplant patients. It aims to find a way to lower the risk of rejection while reducing side effects.
Bordeaux (France)Ages 18 years+ - NCT07195032RecruitingPhase 4
MMR vaccine safety in kids after heart transplant
This trial tests whether the MMR (measles, mumps, rubella) vaccine is safe and works well for children who have had a heart transplant. It may help protect you from these diseases if you haven't had the vaccine or no longer have immunity.
Kansas City, MissouriAges 1–17 - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT06538961Recruiting
Immune registry for BK virus in kidney transplant patients
This study is creating a registry to learn how the immune system responds to BK virus in people who have recently received a kidney transplant from a deceased donor. Researchers hope this information will help improve treatment for BK virus infections.
Richmond, VirginiaAges 18 years+ - NCT05711446Recruiting
Studying repeat urine leaks and bladder infections after kidney transplant
This study looks at how often kidney transplant patients get bladder infections after transplant, especially around routine follow-up visits. It may help the clinic find ways to lower infection risk after transplant.
New York, New YorkAges 18 years+ - NCT06916195Recruiting
CMV virus reactivation in kids after stem cell transplant
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
GenovaAges birth–18 years - NCT05035342RecruitingPhase 3
Fecal transplant to clear resistant gut bacteria
This Phase 3 study tests whether a fecal microbiota transplant (FMT) can eliminate hard-to-treat bacteria in the gut, such as ESBL or carbapenem-resistant bacteria. If it works, it may reduce future infections and antibiotic-resistant illness.
ClichyAges 18–105 - NCT06679257Recruiting
Liquid biopsy for lung transplant damage classification
This study tests a simple blood test (liquid biopsy) to detect and classify damage to a transplanted lung. It aims to find signs of rejection or injury earlier, which could help doctors treat problems sooner.
Gothenburg, Västra Götaland CountyAges 18 years+ - NCT07704255RecruitingPhase 4
Fecal transplant for stubborn H. pylori infection
This study tries a fecal microbiota transplant (placing healthy donor stool into your gut) to get rid of stubborn H. pylori infection that hasn't been cured by standard treatments. It's for people who have failed several rounds of therapy and have a stomach condition that makes eradication important.
Chengdu, SichuanAges 18–80 - NCT06986980Recruiting
Gut Infection After Heart Transplant Study
This study looks at a rare gut infection (microsporidiosis) in people who have had a heart transplant. If you had this infection before 2025 and the diagnosis was made in France, your medical records may be reviewed to learn more about the infection.
Clermont-FerrandAges Any age - NCT07368634RecruitingPhase 1/Phase 2
EBV-TCR-T cells for persistent EBV after stem cell transplant
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
BeijingAges 18–70 - NCT03895593Recruiting
Fecal transplant for stubborn intestinal infections
This study looks at “rescue” fecal microbiota transplantation (FMT), which replaces gut microbes using stool from a screened donor, for intestinal infections that have not improved with standard care. It may help patients whose infection keeps coming back or doesn’t respond to treatment.
Nanjing, JiangsuAges Any age - NCT05266807RecruitingPhase 3
Capsule fecal transplant to prevent C. difficile coming back
This study tests whether taking a capsule form of fecal microbiota transplant (FMT) can help adults with their first C. difficile infection—or a first relapse—get better and reduce repeat episodes. Participants also take specific antibiotics for C. difficile as part of the study process.
Basel, BaselAges 18 years+ - NCT03562741Recruiting
Tracking outcomes of fecal transplant for repeated C. difficile
This study looks at how fecal microbiota transplantation (a transplant of healthy gut bacteria) works for people who get C. difficile infection repeatedly. It also focuses on collecting follow-up information to better understand which patients benefit and how.
Worcester, MassachusettsAges 16 years+ - NCT06554197Recruiting
CMV and EBV immune testing in half-matched stem cell transplant
This trial is for patients with blood disorders who are getting a half-matched stem cell transplant (from a family donor). It tests a new way to measure your immune system's response to two common viruses (CMV and EBV) after transplant, which may help doctors prevent or treat infections better.
Suzhou, JiangsuAges 16–60 - NCT06572462RecruitingPhase 2
Individual ATG dosing for stem cell transplant from unrelated donors
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
BeijingAges 14–65
Hear when a new Transplantation Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for transplantation infection?
- Yes. Clin2 currently lists 113 recruiting transplantation infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transplantation infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transplantation infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.